The overarching goal of the Experimental Therapeutics Program (ETP) is to build a world-class academic center dedicated to bridging basic and translational science for the design of Innovative and Impactful cancer therapies. This program, originally named the Molecular Therapeutics program, was established in December 2004 and brings together an interdisciplinary group of 41 investigators from 15 different departments. Since the last funding cycle the research base of the Experimental Therapeutics Program increased 104% from $7,878,482 to $16,042,852 total annual direct support with a total annual direct research support, of which $3,683,482 is from the NCI. Over the last grant period, there were a total of 539 publications of the Experimental Therapeutics Program members, of which 9.3% are intra-programmatic and 21.1% are inter-programmatic. Led by Shaomeng Wang, Ph.D. and Judith Sebolt-Leopold, Ph,D., the ETP has a strong focus on the rational design and development of small-molecule targeted therapies and serves as a critical link between the basic science and clinical programs. The ETP has four major research themes: I) Identification of novel therapeutic agents and approaches that target key signaling pathways dysregulated in human cancer, II) Improvement of drug delivery systems to address tumor inaccessibility using nanotechnology platforms, III) Execution of lead optimization and preclinical biomarker studies to guide development candidate selection and clinical trial design, IV) Translation of these new cancer medicines and approaches into the clinic.

Public Health Relevance

All of the research in the Experimental Therapeutics Program (ETP) has direct cancer relevance, Research objectives of Program investigators are directed toward the Identification of novel therapeutic agents and approaches for the treatment of cancer and translating these new cancer medicines in the clinic. To maximize ultimate clinical Impact, the ETP serves as a critical link between the basic science and clinical programs to enable the development of personalized therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046592-24
Application #
8300274
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-06-01
Project End
2017-05-31
Budget Start
2012-09-21
Budget End
2013-05-31
Support Year
24
Fiscal Year
2012
Total Cost
$540,700
Indirect Cost
$192,763
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90

Showing the most recent 10 out of 1493 publications